Terasaki Institute for Biomedical Innovation Announces Partnership with Rousselot

January 12, 2022

– The Terasaki Institute for Biomedical Innovation (TIBI), a non-profit multidisciplinary bioengineering research institution, announces their partnership with Darling Ingredients’ health brand, Rousselot®, the world leader in collagen-based solutions, with more than 130 years of gelatin and collagen expertise.

With their long-standing experience in tissue engineering and regeneration, bio-fabrication using 3D printing and engineering micro- and nano-scale medical devices, TIBI has relied heavily on the use of modified and functionalized gelatin biomaterials for their research and experimentation. In doing so, they have developed valuable insights into gelatin’s behavior and have used this knowledge to optimize and tune gelatin biomaterials for various biomedical applications.

Decreasing Cancer Drugs’ Side Effects

Scientists develop plant-based “hairy nanocrystals” to remove excess chemotherapy drugs from the blood

January 6, 2022

– Millions of people around the globe are affected by cancer each year; more than 39% of men and women are diagnosed with cancer during their lifetime. Chemotherapy is the most commonly employed, standard cancer treatment and targeted delivery of these drugs to the tumor site increases their effectiveness. However, excess drugs may still circulate to the rest of the body and cause multiple side effects, including anemia, chronic infections, hair loss, jaundice and fever.

Terasaki Institute for Biomedical Innovation  Year in Review 2021

December 16, 2021

(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) has had a busy and productive year and has grown in many ways.

On the leadership side, TIBI is proud to welcome its new Chief Scientific Officer, Xiling Shen, Ph.D. Dr Shen is a highly accomplished scientist whose works span the multidisciplinary fields of biomedical engineering, computational techniques, cancer biology, and multi-omics methodology.

Antiviral Materials Inspired by Rose Thorns

Fibrous material may be used as antiviral agent in garments, face coverings and bandages

December 16, 2021

(LOS ANGELES) – Billions of people around the world suffer from herpes simplex virus (HSV) infections; the severity of these infections range from no symptoms at all to fatal complications. There are two types of herpes viruses: HSV-1, which infects the eyes and oral cavity, and HSV-2, which infects the genitalia.

Current treatments include antiviral drugs which are either injected or applied topically as ointments; these drugs interfere with virus replication to keep their population in check. Other treatments are available such as vaccines, which stimulate antiviral immune responses, or immune response-modifying drugs.

TIBI Innovation – COP 26

December 16, 2021

(LOS ANGELES) – Established in 1992, in response to the scientific evidence supporting a rapidly changing global climate, the United Nations Framework Convention on Climate Change (UNFCCC) was adopted and became its own UN entity.

The Conference of the Parties (COP) was established as the primary annual UNFCCC conference dedicated to the intergovernmental climate change negotiations of the 197 parties (countries).

Skin Sensing Made Easier: Improved Methods Facilitate Monitoring of Body Movement and Health

Scientists simplify fabrication methods and model human skin structure in designing wearable sensors

December 15, 2021

(LOS ANGELES) – From wide-ranging body movements as minute as a pulse to the various movements of joints, muscles and limbs, wearable pressure sensors placed directly on the skin may be used in myriad ways to monitor health. Other types of skin sensors can monitor health indicators through measurement of sweat and temperature on the skin’s surface.

Scientists From the Terasaki Institute for Biomedical Innovation Ranked Among Most Highly Cited Researchers for 2021

December 3, 2021

(LOS ANGELES) – A recent announcement of their 2021 highly cited researchers was made by Clarivate Analytics. The rankings are based on research papers published from January 2010 to December 2020, with each author assigned to one of 22 fields in science and social science. Each scientist on the list is ranked in the top 1% for highly cited papers in their field.

Two scientists on the list are from the Terasaki Institute for Biomedical Innovation (TIBI); Dr. Ali Khademhosseini was named under the three categories of Biology and Biochemistry, Materials Science, and Pharmacology and Toxicology, and Dr. Mehmet R. Dokmeci was named under the Cross-Field category. Follow the links to bios and lists of their 2020 publications.

Dr. Ali Khademhosseini, CEO and Founding Director
Dr. Mehmet R. Dokmeci, Associate Professor
Terasaki Institute Welcomes Academic Entrepreneur, Dr. Xiling Shen, as new Chief Scientific Officer

November 18, 2021

(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) announces the hiring of its Chief Scientific Officer, Professor Xiling Shen. Professor Shen is a highly-accomplished scientist whose works span the multidisciplinary fields of biomedical engineering, computational techniques, cancer biology, and multi-omics methodologies.